Cargando…

Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices

BACKGROUND: Increasing pharmaceutical expenditure challenges the sustainability and accessibility of healthcare systems across Europe. Confidentiality restraints hinder assessment of actual prices of Orphan Medicinal Products (OMPs). Hence, we assessed the real prices of brand-name OMPs around marke...

Descripción completa

Detalles Bibliográficos
Autores principales: Dane, Aniek, Klein Gebbink, Anne-Sophie, Brugma, Jan-Dietert, Degrassat-Théas, Albane, Hug, Martin J., Houlind, Morten B., Paubel, P., van der Kuy, P. Hugo M., Uyl-de Groot, Carin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628053/
https://www.ncbi.nlm.nih.gov/pubmed/37751107
http://dx.doi.org/10.1007/s40258-023-00832-6
_version_ 1785131670472491008
author Dane, Aniek
Klein Gebbink, Anne-Sophie
Brugma, Jan-Dietert
Degrassat-Théas, Albane
Hug, Martin J.
Houlind, Morten B.
Paubel, P.
van der Kuy, P. Hugo M.
Uyl-de Groot, Carin A.
author_facet Dane, Aniek
Klein Gebbink, Anne-Sophie
Brugma, Jan-Dietert
Degrassat-Théas, Albane
Hug, Martin J.
Houlind, Morten B.
Paubel, P.
van der Kuy, P. Hugo M.
Uyl-de Groot, Carin A.
author_sort Dane, Aniek
collection PubMed
description BACKGROUND: Increasing pharmaceutical expenditure challenges the sustainability and accessibility of healthcare systems across Europe. Confidentiality restraints hinder assessment of actual prices of Orphan Medicinal Products (OMPs). Hence, we assessed the real prices of brand-name OMPs around market exclusivity expiry (MEE). OBJECTIVE: We aimed to explore developments in published list prices (LPs) and confidential hospital purchase prices (PPs) of brand-name OMPs relative to their market exclusivity status in Western European countries with similar GDPs. METHODS: We analyzed LPs and PPs of 13 selected OMPs purchased by university hospitals in Western European countries between 2000 and 2020. For confidentially reasons, proportions were used, with the Dutch LPs of the selected OMPs at the year of MEE serving as reference values. PPs included pre-purchase discounts. Rebates were not considered. RESULTS: Data were analyzed from hospitals in Denmark (DK) (n = 1), France (FR) (n = 1), Germany (DE) (n = 2), and the Netherlands (NL) (n = 1). Average LPs and PPs of included OMPs dropped gradually but limited over time, with no explicit price drop after MEE. LP levels differed more per country than PP levels: LP range before MEE was 164% (DE)–101% (FR) and after MEE was 135% (DE)–82% (FR); PP range before MEE was 150% (DE)–102% (FR) and after MEE was 107% (DE)–80% (FR). Overall differences between LPs and PPs were < 3% in all countries, except for Denmark. CONCLUSION: No evident price drops of included brand-name OMPs were observed around MEE and differences in purchase prices are modest in the selected Western European countries. Results were not subject to significance testing. More robust data are needed to strengthen negotiations with suppliers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00832-6.
format Online
Article
Text
id pubmed-10628053
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106280532023-11-08 Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices Dane, Aniek Klein Gebbink, Anne-Sophie Brugma, Jan-Dietert Degrassat-Théas, Albane Hug, Martin J. Houlind, Morten B. Paubel, P. van der Kuy, P. Hugo M. Uyl-de Groot, Carin A. Appl Health Econ Health Policy Original Research Article BACKGROUND: Increasing pharmaceutical expenditure challenges the sustainability and accessibility of healthcare systems across Europe. Confidentiality restraints hinder assessment of actual prices of Orphan Medicinal Products (OMPs). Hence, we assessed the real prices of brand-name OMPs around market exclusivity expiry (MEE). OBJECTIVE: We aimed to explore developments in published list prices (LPs) and confidential hospital purchase prices (PPs) of brand-name OMPs relative to their market exclusivity status in Western European countries with similar GDPs. METHODS: We analyzed LPs and PPs of 13 selected OMPs purchased by university hospitals in Western European countries between 2000 and 2020. For confidentially reasons, proportions were used, with the Dutch LPs of the selected OMPs at the year of MEE serving as reference values. PPs included pre-purchase discounts. Rebates were not considered. RESULTS: Data were analyzed from hospitals in Denmark (DK) (n = 1), France (FR) (n = 1), Germany (DE) (n = 2), and the Netherlands (NL) (n = 1). Average LPs and PPs of included OMPs dropped gradually but limited over time, with no explicit price drop after MEE. LP levels differed more per country than PP levels: LP range before MEE was 164% (DE)–101% (FR) and after MEE was 135% (DE)–82% (FR); PP range before MEE was 150% (DE)–102% (FR) and after MEE was 107% (DE)–80% (FR). Overall differences between LPs and PPs were < 3% in all countries, except for Denmark. CONCLUSION: No evident price drops of included brand-name OMPs were observed around MEE and differences in purchase prices are modest in the selected Western European countries. Results were not subject to significance testing. More robust data are needed to strengthen negotiations with suppliers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40258-023-00832-6. Springer International Publishing 2023-09-26 2023 /pmc/articles/PMC10628053/ /pubmed/37751107 http://dx.doi.org/10.1007/s40258-023-00832-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Dane, Aniek
Klein Gebbink, Anne-Sophie
Brugma, Jan-Dietert
Degrassat-Théas, Albane
Hug, Martin J.
Houlind, Morten B.
Paubel, P.
van der Kuy, P. Hugo M.
Uyl-de Groot, Carin A.
Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
title Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
title_full Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
title_fullStr Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
title_full_unstemmed Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
title_short Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
title_sort prices of orphan drugs in four western european countries before and after market exclusivity expiry: a cross-country comparison of list prices and purchase prices
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628053/
https://www.ncbi.nlm.nih.gov/pubmed/37751107
http://dx.doi.org/10.1007/s40258-023-00832-6
work_keys_str_mv AT daneaniek pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices
AT kleingebbinkannesophie pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices
AT brugmajandietert pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices
AT degrassattheasalbane pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices
AT hugmartinj pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices
AT houlindmortenb pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices
AT paubelp pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices
AT vanderkuyphugom pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices
AT uyldegrootcarina pricesoforphandrugsinfourwesterneuropeancountriesbeforeandaftermarketexclusivityexpiryacrosscountrycomparisonoflistpricesandpurchaseprices